ALXO נכסי החברה ALX Oncology

The current financial standing of ALX Oncology Holdings (ALXO) relies on capital raising, as the company lacks commercial products and maintains a negative cash flow. Future revenues are expected to stem from the commercialization of the innovative drug Evorpacept for the therapy of oncological diseases. This chart of the company on the GURU.Markets platform shows that total assets amount to 128.07. The business strives for leadership in immuno-oncology by developing Evorpacept for the targeted destruction of tumors without harming the blood.

Assessing a company's resource base is critical for selecting stocks with a high margin of fundamental strength. This indicator, reconstructed via return on assets (ROA), measures the totality of controlled resources, which for ALX Oncology (ALXO) reflects the capitalization of innovative developments in oncology blockers and the potential for future pricing power, capturing the business value trend through the company's current asset levels.